drugset / Trial / NCT06952634
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This a phase 1, open label, single dose, parallel cohort study to determine the pharmacokinetics (PK) of study drug (ESK-001) in healthy volunteer participants, and participants with mild, moderate, and severe hepatic impairment.
Timeline
- Start
- 2025-04-29
- Primary completion
- 2026-03-24
- Completion
- 2026-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENVUCITINIB | Small molecule | — | Oral |
Indications
No indication recorded.